One of the most common misperceptions relating to non-dilutive funding for life science R&D is that the SBIR/STTR program is the main and even only funding resource available for the life science industry. Companies and investors alike must know that although it is an important and sometimes relevant program, the SBIR/STTR program is a small, […]
Writing proposals for Federal grants is a time consuming task that requires much planning and administration. This process typically takes 3-6 weeks to complete for a standard high quality application; more complex applications may take longer. However, the brief periods often allotted between release of a funding opportunity announcement and its deadline, as well as […]
As life science research is becoming more complicated, requiring collaborative activity and significant resources, funding agencies, such as NIH and DOD, have shifted significant portions of their budgets towards supporting large scale, multi-project clinical activities of both academic institutions and companies. The funding agencies put forth great effort in creating and allocating budgets to programs […]
FreeMind sustains a growing network of leading companies and organizations, all with a strong and common interest in assisting the life science market and creating a common ground and collaborative framework for academia-industry collaborations. Our extensive and intimate understanding of the market, coupled with our designated knowledge of non dilutive funding sources and their promotion […]
Non dilutive funding is available for every conceivable kind of research or development effort, whether it is an academic or industry project. Government agencies, as well as state organizations and private foundations, release daily hundreds of different solicitations covering topics that are of interest to public health and medical and life science research. Although these […]
Industry-Academic partnerships drive life science discoveries to market, and the importance of sustaining and nurturing these relationships is high on the agenda of both industry and academic leaders. Over the past several years we are witnessing a changing direction at the NIH and other government granting agencies aimed at supporting these relationships. We will give […]